Boston Scientific (BSX) Falls More Steeply Than Broader Market: What Investors Need to Know

31.12.24 00:15 Uhr

Werte in diesem Artikel
Aktien

86,50 EUR 0,50 EUR 0,58%

Indizes

5.868,6 PKT -13,1 PKT -0,22%

Boston Scientific (BSX) closed the most recent trading day at $89.68, moving -1.08% from the previous trading session. The stock's change was less than the S&P 500's daily loss of 1.07%. Elsewhere, the Dow saw a downswing of 0.97%, while the tech-heavy Nasdaq depreciated by 1.19%.Heading into today, shares of the medical device manufacturer had 0% over the past month, outpacing the Medical sector's loss of 5.64% and the S&P 500's loss of 0.36% in that time.The investment community will be paying close attention to the earnings performance of Boston Scientific in its upcoming release. It is anticipated that the company will report an EPS of $0.65, marking a 18.18% rise compared to the same quarter of the previous year. Meanwhile, the Zacks Consensus Estimate for revenue is projecting net sales of $4.4 billion, up 18.15% from the year-ago period.For the full year, the Zacks Consensus Estimates are projecting earnings of $2.46 per share and revenue of $16.59 billion, which would represent changes of +20% and +16.48%, respectively, from the prior year.It's also important for investors to be aware of any recent modifications to analyst estimates for Boston Scientific. Recent revisions tend to reflect the latest near-term business trends. As such, positive estimate revisions reflect analyst optimism about the company's business and profitability.Our research demonstrates that these adjustments in estimates directly associate with imminent stock price performance. To take advantage of this, we've established the Zacks Rank, an exclusive model that considers these estimated changes and delivers an operational rating system.The Zacks Rank system, which varies between #1 (Strong Buy) and #5 (Strong Sell), carries an impressive track record of exceeding expectations, confirmed by external audits, with stocks at #1 delivering an average annual return of +25% since 1988. Over the past month, there's been no change in the Zacks Consensus EPS estimate. Boston Scientific is currently sporting a Zacks Rank of #2 (Buy).Digging into valuation, Boston Scientific currently has a Forward P/E ratio of 36.85. Its industry sports an average Forward P/E of 24.71, so one might conclude that Boston Scientific is trading at a premium comparatively.Investors should also note that BSX has a PEG ratio of 2.67 right now. The PEG ratio bears resemblance to the frequently used P/E ratio, but this parameter also includes the company's expected earnings growth trajectory. The Medical - Products industry currently had an average PEG ratio of 2.29 as of yesterday's close.The Medical - Products industry is part of the Medical sector. This group has a Zacks Industry Rank of 126, putting it in the top 50% of all 250+ industries.The Zacks Industry Rank is ordered from best to worst in terms of the average Zacks Rank of the individual companies within each of these sectors. Our research shows that the top 50% rated industries outperform the bottom half by a factor of 2 to 1.Be sure to follow all of these stock-moving metrics, and many more, on Zacks.com.Zacks Naming Top 10 Stocks for 2025Want to be tipped off early to our 10 top picks for the entirety of 2025?History suggests their performance could be sensational.From 2012 (when our Director of Research Sheraz Mian assumed responsibility for the portfolio) through November, 2024, the Zacks Top 10 Stocks gained +2,112.6%, more than QUADRUPLING the S&P 500’s +475.6%. Now Sheraz is combing through 4,400 companies to handpick the best 10 tickers to buy and hold in 2025. Don’t miss your chance to get in on these stocks when they’re released on January 2.Be First to New Top 10 Stocks >>Want the latest recommendations from Zacks Investment Research? Today, you can download 7 Best Stocks for the Next 30 Days. Click to get this free report Boston Scientific Corporation (BSX): Free Stock Analysis ReportTo read this article on Zacks.com click here.Zacks Investment ResearchWeiter zum vollständigen Artikel bei Zacks

Ausgewählte Hebelprodukte auf Boston Scientific

Mit Knock-outs können spekulative Anleger überproportional an Kursbewegungen partizipieren. Wählen Sie einfach den gewünschten Hebel und wir zeigen Ihnen passende Open-End Produkte auf Boston Scientific

NameHebelKOEmittent
NameHebelKOEmittent
Wer­bung

Quelle: Zacks

Nachrichten zu Boston Scientific Corp.

Wer­bung

Analysen zu Boston Scientific Corp.

DatumRatingAnalyst
03.09.2019Boston Scientific OverweightBarclays Capital
16.10.2018Boston Scientific OverweightBarclays Capital
07.09.2018Boston Scientific Strong BuyNeedham & Company, LLC
06.07.2018Boston Scientific Strong BuyNeedham & Company, LLC
26.04.2018Boston Scientific Strong BuyNeedham & Company, LLC
DatumRatingAnalyst
03.09.2019Boston Scientific OverweightBarclays Capital
16.10.2018Boston Scientific OverweightBarclays Capital
07.09.2018Boston Scientific Strong BuyNeedham & Company, LLC
06.07.2018Boston Scientific Strong BuyNeedham & Company, LLC
26.04.2018Boston Scientific Strong BuyNeedham & Company, LLC
DatumRatingAnalyst
28.04.2016Boston Scientific NeutralWedbush Morgan Securities Inc.
04.05.2015Boston Scientific HoldDeutsche Bank AG
05.02.2015Boston Scientific HoldDeutsche Bank AG
30.09.2014Boston Scientific HoldNeedham & Company, LLC
07.01.2013Boston Scientific haltenDeutsche Bank Securities
DatumRatingAnalyst
13.04.2010Boston Scientific "sell"Goldman Sachs Group Inc.
17.03.2010Boston Scientific DowngradeGoldman Sachs Group Inc.
10.10.2008Boston Scientific below averageCaris & Company, Inc.
02.10.2008Boston Scientific DowngradeMerrill Lynch & Co., Inc.
13.12.2007Boston Scientific underperformFriedman, Billings Ramsey & Co

Um die Übersicht zu verbessern, haben Sie die Möglichkeit, die Analysen für Boston Scientific Corp. nach folgenden Kriterien zu filtern.

Alle: Alle Empfehlungen

Buy: Kaufempfehlungen wie z.B. "kaufen" oder "buy"
Hold: Halten-Empfehlungen wie z.B. "halten" oder "neutral"
Sell: Verkaufsempfehlungn wie z.B. "verkaufen" oder "reduce"